NCT01404156
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma treatment 2 / 3 completed NCT05705635
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer treatment 2 recruiting NCT04014075
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) treatment 2 completed NCT05315830
A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric No drug interventions treatment 1 unknown_status NCT06059495
Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study treatment 2 recruiting NCT04984733
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer treatment 2 recruiting NCT01786278
Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer No drug interventions treatment 2 / 3 unknown_status NCT01271322
Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG) No drug interventions treatment 2 terminated NCT04062656
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG treatment 2 active_not_recruiting NCT05419349
Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database No drug interventions Not Available Not Available completed NCT02287129
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction treatment 2 completed NCT00849615
Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction treatment 2 completed NCT02509286
Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus treatment 3 active_not_recruiting NCT00737373
Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer treatment 2 completed NCT03647540
The Application of Fluorescence Laparoscopy in the Treatment of Adenocarcinoma of the Esophagogastric Junction No drug interventions treatment Not Available unknown_status NCT01726452
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) treatment 3 completed NCT04423354
A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG No drug interventions treatment Not Available unknown_status NCT05001360
Study of FMT Combined With Nivolumab in Gastric Cancer treatment Not Available withdrawn NCT06461910
Efficacy and Safety of Anti-PD-1, Thymosin, and SOX in Neoadjuvant Treatment of cStage III Gastric/GEJ Adenocarcinoma No drug interventions treatment 2 not_yet_recruiting NCT05170503
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma treatment 2 recruiting NCT06482788
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study treatment 2 recruiting NCT04153058
Clinical Outcomes of Robotic Versus Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III AEG No drug interventions treatment Not Available enrolling_by_invitation NCT00719550
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer treatment 1 / 2 completed NCT04683939
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors treatment 1 / 2 terminated NCT06628310
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma treatment 2 not_yet_recruiting NCT06157892
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors treatment 1 / 2 recruiting NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies treatment 1 active_not_recruiting NCT05002127
A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06) treatment 2 / 3 recruiting NCT05111626
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. treatment 3 recruiting NCT05836584
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer treatment 2 recruiting NCT05902988
A Phase I/II Study of VLS-1488 in Subjects with Advanced Cancer No drug interventions treatment 1 / 2 recruiting NCT06131840
A Study of PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT06324357
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread treatment 1 / 2 recruiting NCT06549816
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors treatment 1 recruiting NCT06586294
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma treatment 1 / 2 not_yet_recruiting NCT05034887
Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma treatment 2 recruiting NCT06206733
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma treatment 3 recruiting NCT02389751
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer treatment 1 completed NCT03852251
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma treatment 1 / 2 completed NCT04762953
Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis treatment 2 recruiting NCT02898077
A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer treatment 3 completed NCT02891447
Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer treatment 2 completed NCT02370498
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) treatment 3 completed NCT04375605
Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ treatment 3 active_not_recruiting NCT06196697
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer treatment 2 recruiting NCT06155383
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. treatment 2 recruiting NCT06560528
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression treatment 2 recruiting NCT02335411
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) treatment 2 completed NCT06206278
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma treatment 2 terminated NCT03019588
Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) treatment 3 terminated NCT04805307
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 treatment 1 recruiting NCT04510285
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection treatment 2 terminated NCT02530437
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer treatment 1 / 2 terminated NCT03196232
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer treatment 2 completed NCT06353152
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma No drug interventions treatment 1 recruiting NCT04447352
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) treatment 3 recruiting NCT04060342
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma treatment 1 terminated NCT04152499
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies treatment 1 / 2 recruiting NCT04290806
Registry Platform Gastric/Esophageal Cancer (SAPHIR) No drug interventions Not Available Not Available recruiting NCT05753306
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study treatment 2 recruiting NCT04609813
Esophageal cAncer Screening Trial No drug interventions Not Available Not Available completed NCT03083613
Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma treatment 2 completed NCT03966118
Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma treatment 2 unknown_status NCT05918419
Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction treatment 2 recruiting NCT04656041
Folfox+Irinotecan+Chemort In Esophageal Cancer treatment 2 recruiting NCT02314117
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer treatment 3 completed NCT04499924
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer treatment 2 / 3 completed NCT03429816
OPPOSITE: Outcome Prediction Of Systemic Treatment in Esophagogastric Carcinoma No drug interventions diagnostic Not Available active_not_recruiting NCT02589496
Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis treatment 2 completed NCT02962063
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer treatment 1 / 2 recruiting NCT03760822
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients treatment 2 active_not_recruiting NCT02539225
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma treatment 2 completed NCT03122548
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers treatment 2 terminated NCT02007148
MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer treatment 2 unknown_status NCT06243757
A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers No drug interventions Not Available Not Available recruiting NCT05472857
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression No drug interventions treatment 1 recruiting NCT04140526
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC treatment 1 / 2 recruiting NCT05156866
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer No drug interventions treatment 1 recruiting NCT04581473
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection treatment 1 / 2 recruiting NCT02077673
Gastric Microperfusion in Patients Undergoing Gastroesophageal Resections No drug interventions Not Available Not Available completed NCT04933227
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) treatment 2 terminated NCT05311176
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) treatment 2 active_not_recruiting NCT03170960
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors treatment 1 / 2 active_not_recruiting NCT02830594
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer treatment 2 completed NCT02193594
Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma treatment 2 / 3 unknown_status NCT05019794
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations treatment 2 unknown_status NCT03802591
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma treatment 3 completed NCT03604991
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery treatment 2 / 3 suspended NCT05419362
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer treatment 2 active_not_recruiting NCT00964080
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma treatment 1 / 2 unknown_status NCT04510129
A Multicenter Cancer Biospecimen Collection Study No drug interventions Not Available Not Available recruiting NCT04850729
Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. No drug interventions Not Available Not Available recruiting NCT02952989
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors treatment 1 terminated NCT05394740
Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy treatment 1 / 2 active_not_recruiting NCT05159440
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer No drug interventions treatment 1 active_not_recruiting NCT03739801
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma treatment 1 / 2 withdrawn NCT04089904
Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma treatment 2 terminated NCT02730546
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery treatment 1 / 2 completed NCT01962246
Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction treatment 2 / 3 completed NCT02307812
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France Not Available Not Available no_longer_available NCT02082210
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer treatment 1 / 2 completed NCT04161781
A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer No drug interventions Not Available Not Available completed NCT04661150
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction treatment 2 active_not_recruiting NCT02128243
Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer treatment 2 completed NCT03735290
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer treatment 1 terminated NCT01196390
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer treatment 3 completed NCT03986502
Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma No drug interventions health_services_research Not Available completed NCT06047379
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis treatment 1 / 2 recruiting NCT02572687
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies treatment 1 completed NCT03724851
Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer treatment 1 / 2 active_not_recruiting NCT02628951
Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis treatment 2 completed NCT02514551
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer treatment 2 completed NCT06341647
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 treatment 1 not_yet_recruiting NCT03395847
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma treatment 0 completed NCT05678205
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors treatment 1 / 2 not_yet_recruiting NCT05008783
A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma treatment 3 active_not_recruiting NCT02443883
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer treatment 2 completed NCT03707028
A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer treatment 1 / 2 terminated NCT06340711
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma treatment 2 recruiting NCT00515411
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma treatment 2 completed NCT06038578
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer treatment 2 recruiting NCT03686488
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma treatment 2 completed NCT03421288
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness treatment 2 recruiting NCT01379807
Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma treatment 2 unknown_status NCT03592407
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer treatment 2 withdrawn NCT04915807
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel Not Available Not Available unknown_status NCT05802056
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis treatment 1 recruiting NCT03986385
Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction treatment 3 unknown_status NCT06265285
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program health_services_research 2 recruiting NCT06028737
Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer treatment 2 / 3 recruiting NCT04389632
A Study of SGN-B6A in Advanced Solid Tumors treatment 1 recruiting NCT03221400
PEN-866 in Patients With Advanced Solid Malignancies treatment 1 / 2 unknown_status NCT06121700
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer treatment 2 recruiting NCT04263870
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction treatment 2 unknown_status NCT06266299
A Study of KK2269 in Adult Participants With Solid Tumors treatment 1 recruiting NCT04615013
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer treatment 1 recruiting NCT03894618
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas No drug interventions treatment 1 completed NCT04704934
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) treatment 3 recruiting NCT03175224
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors treatment 2 recruiting NCT05476796
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer treatment 2 recruiting NCT04208958
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer treatment 1 / 2 completed NCT06454435
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer treatment 2 not_yet_recruiting NCT05567835
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer treatment 2 recruiting NCT05393986
Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors No drug interventions treatment 1 recruiting NCT03511222
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors treatment 1 terminated NCT06221748
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy treatment 2 / 3 recruiting NCT03615326
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) treatment 3 active_not_recruiting NCT03349866
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction treatment 2 unknown_status NCT05709574
Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer treatment 2 recruiting NCT03368131
Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study treatment 2 unknown_status NCT03979131
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) treatment 2 active_not_recruiting NCT05203627
Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery No drug interventions supportive_care Not Available active_not_recruiting NCT04808791
iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma treatment 2 completed NCT05111444
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma treatment 2 unknown_status NCT05052801
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression treatment 3 active_not_recruiting NCT04032704
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors treatment 2 terminated NCT04018872
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer treatment 2 recruiting NCT05334069
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection No drug interventions Not Available Not Available recruiting NCT00763646
Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma treatment 2 unknown_status NCT02864381
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma treatment 2 completed NCT04344795
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors treatment 1 active_not_recruiting NCT04361708
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies treatment 1 recruiting NCT02391038
MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C treatment 1 terminated NCT03413397
Lenvatinib Mesylate and Pembrolizumab in Treating Patients With Metastatic or Recurrent Gastric or Gastroesophageal Cancer treatment 2 recruiting NCT02678182
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial treatment 2 recruiting NCT01359397
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Not Available 2 unknown_status NCT06504615
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France Not Available Not Available not_yet_recruiting NCT03283761
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma treatment 2 completed NCT03141034
Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma treatment 2 completed NCT05365581
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer treatment 1 recruiting NCT05964543
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors treatment 1 / 2 recruiting NCT02680990
Resilience and Exercise in Advanced Cancer Treatment No drug interventions treatment Not Available completed NCT01333033
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy treatment 2 completed NCT00732745
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction treatment 1 terminated NCT01243398
Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy No drug interventions treatment 3 completed NCT00891878
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction treatment 2 completed NCT00061932
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach treatment 2 completed NCT00991952
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery treatment 2 completed NCT01183559
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery treatment 1 completed NCT00064259
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer treatment 1 / 2 terminated NCT00938470
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction treatment 2 completed NCT00978549
Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer treatment 3 completed NCT01216813
Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer No drug interventions Not Available Not Available completed NCT01360086
Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction treatment 2 completed NCT01107639
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery treatment 3 completed NCT01212822
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer treatment 2 completed NCT04681248
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors Not Available Not Available available NCT02037048
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma treatment 2 active_not_recruiting NCT01472029
Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach treatment 2 completed NCT00982592
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer treatment 2 completed NCT00963092
Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer No drug interventions Not Available Not Available unknown_status NCT04028167
Induction FLOT with CROSS CRT for Esophageal Cancer No drug interventions treatment 2 recruiting NCT01260701
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer No drug interventions treatment 2 completed NCT02344810
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer treatment 1 / 2 withdrawn NCT01561014
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction treatment 1 completed NCT02013154
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab treatment 1 completed NCT01855854
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH treatment 2 completed NCT01851928
Validation of a Nutrition Screening Tool No drug interventions Not Available Not Available completed NCT01307956
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer treatment 2 terminated NCT01523015
Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction No drug interventions treatment 2 / 3 unknown_status NCT01395537
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) treatment 1 / 2 terminated NCT01939275
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer No drug interventions diagnostic Not Available active_not_recruiting NCT00253370
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer treatment 2 completed NCT01231399
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer treatment 1 / 2 completed NCT01582906
A Survivorship Care Plan for Gynaecological Cancer Patients No drug interventions Not Available Not Available completed NCT03307941
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA treatment 1 / 2 withdrawn NCT00084617
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma treatment 2 completed NCT02485834
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer treatment 2 terminated NCT02443324
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer treatment 1 completed NCT00045526
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer treatment 2 completed NCT01640782
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach treatment 3 completed NCT01123473
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer treatment 2 terminated NCT00607594
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer treatment 2 completed NCT02918162
Perioperative Chemo and Pembrolizumab in Gastric Cancer treatment 2 completed NCT02234180
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery treatment 2 terminated NCT01498289
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer treatment 2 completed NCT01178944
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer treatment 2 completed NCT01705340
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery treatment 1 terminated NCT00084604
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma treatment 2 completed NCT00757172
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction treatment 2 completed NCT04773769
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas No drug interventions treatment Not Available unknown_status NCT01612546
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery treatment 2 completed NCT03722108
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas treatment 1 / 2 terminated NCT04430738
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers treatment 1 / 2 active_not_recruiting NCT02564367
Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction treatment 1 / 2 completed NCT01129206
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy treatment 2 completed NCT00216008
Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation. treatment 2 terminated NCT01182610
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma treatment 2 terminated NCT05715931
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma treatment 2 recruiting NCT03302403
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors treatment Not Available unknown_status NCT04891900
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma treatment Not Available active_not_recruiting NCT03734913
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors No drug interventions treatment 1 unknown_status NCT01697917
Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction No drug interventions treatment 3 unknown_status NCT01095120
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer treatment 2 unknown_status NCT06222944
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA treatment 2 not_yet_recruiting NCT06300879
A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique No drug interventions treatment Not Available recruiting NCT05505461
Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma No drug interventions treatment 2 not_yet_recruiting NCT05872685
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) treatment 2 recruiting NCT05829213
A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal Gastrectomy No drug interventions treatment Not Available recruiting NCT05970627
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma treatment 2 not_yet_recruiting NCT04910789
Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction No drug interventions treatment Not Available recruiting NCT05729646
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma treatment 2 recruiting NCT04813523
Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma treatment 2 unknown_status NCT06299163
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors No drug interventions treatment 1 recruiting